argenx Reports Breakthrough Data from ADHERE Study in CIDP Published in The Lancet Neurology

argenx ARGX, a global biotechnology company, has reached a significant milestone with the publication of its ADHERE study data in The Lancet Neurology, showcasing the impact of VYVGART^®Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) on patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). The ADHERE study has been recognized as the most comprehensive and innovative trial for CIDP patients thus far.

Pivotal Trial Findings for CIDP Patients

The trial's outcomes are a beacon of hope for individuals living with this rare neurological disorder. The use of VYVGART^®Hytrulo led to a marked reduction in the progression of the disease, lowered the risk of relapse, and offered a rapid onset of action, showcasing the potential of this treatment to significantly alter the management of CIDP. The scale and innovative design of the ADHERE study provide compelling evidence to support the therapeutic benefits of efgartigimod alfa and hyaluronidase-qvfc, positioning argenx ARGX at the forefront of CIDP research and treatment.

Innovative Approach to CIDP Treatment

The success of VYVGART^®Hytrulo is attributed not only to its ability to stymie the disease's progression but also to enhance the quality of life for patients by reducing relapse frequencies. These promising results are pivotal for the future of CIDP treatment and speak volumes of the rigorous research and development that argenx ARGX has committed to in the fight against chronic autoimmune conditions.

argenx, CIDP, ADHERE